220355-63-5
220355-63-5 性质
| 沸点 | 745.5±70.0 °C(Predicted) |
|---|---|
| 密度 | 1.23±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜：≥28mg/mL（45.62mM） |
| 形态 | 固体 |
| 酸度系数(pKa) | 9.76±0.50(Predicted) |
| 颜色 | 白色至米白色 |
220355-63-5 用途与合成方法
Ki: 0.41 μM (Urokinase-type plasminogen activator (uPA))
Serine protease
UKI-1 (WX-UK1; 0.1-1.0 μg/mL) treatment shows a decrease of tumor cell invasion by up to 50% is achieved in both models with the SCCHN line FaDu and the cervical carcinoma line HeLa.
UKI-1 (WX-UK1) interferes with the plasminogen activation system at 2 levels: it inhibits plasmin formation directly and via inhibition of uPA. In vitro invasion models with highly invasive fibrosarcoma and breast cancer cells showed that UKI-1 effectively inhibits migration of the cells through fibrin matrices.
UKI-1 (WX-UK1) treatment has antimetastatic activities that significantly reduces the number of metastatic lesions and tumor growth in metastasizing rat pancreatic and mammary adenocarcinoma tumor models.
220355-63-5 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-100415 | 220355-63-5 | 220355-63-5 | 1mg | 1500 |
| 2024-11-08 | HY-100415 | 220355-63-5 | 220355-63-5 | 5mg | 3500 |
